Chief Physician, expert in the International Department, Associate Professor, other high-level talent in Hainan Province, and supervisor of masters students. With over 30 years of experience in clinical oncology, teaching, and scientific research, she graduated from Southeast University and continued her studies for a masters degree at the same university. She has worked at the First Affiliated Hospital of Nanjing Medical University for 26 years and has also pursued further studies at the Cancer Research Center of the University of Colorado, USA. She was selected by the Education Department of Jiangsu Province to study at the Cancer Research Center of the University of Colorado, USA, and participated in workshops and discussions related to tumor drug clinical trials at the Harvard School of Public Health. Additionally, she has been a key researcher in multiple international and domestic multicenter clinical studies focusing on gastric and intestinal cancers. She has undertaken and participated in numerous scientific research projects in Jiangsu Province and at Nanjing Medical University, primarily dedicated to exploring the mechanisms of multidrug resistance in tumor chemotherapy and reversing multidrug resistance. Several research outcomes have been clinically applied, and she has published over 30 academic papers.

She is proficient in the comprehensive treatment of various malignant tumors, such as head and neck malignancies, lung cancer, breast cancer, digestive tract tumors (liver cancer, gastric cancer, colorectal cancer, etc.), and genitourinary system tumors (cervical cancer, ovarian cancer, bladder cancer, etc.). The comprehensive treatment includes chemotherapy, biological immunotherapy (molecular targeted therapy, cellular immunotherapy, etc.), endocrine therapy and traditional Chinese medicine. Based on MDT, he conducts comprehensive treatments mainly including neoadjuvant chemotherapy, postoperative adjuvant chemotherapy and palliative chemotherapy. In particular, she has a extensive knowledge of the clinical and basic research of lung cancer and breast cancer, is committed to the medical treatment of tumors and the research of molecular targeted drugs, and participates in and is responsible for the introduction and clinical application of new international anti-cancer drugs in the hospital.

Malignant tumor targeting and immunological therapy

Executive Chairman, Council of Hainan Tumor Control Association 
Member of the Third Council of Hainan Immunological Society 
Chairman of the Tumor Immunology Committee of Hainan Immunology Society 
Standing member of the Sixth Professional Committee of Oncology Branch of Hainan Provincial Medical Association 
Member of the Third Session of the Cancer Health Professional Committee of Hainan Anti-Cancer Association 
Standing member of Palliative Care Sub-Committee of Beijing Cancer Prevention and Treatment Research Association  
Standing member of the First session of the Breast Cancer Professional Committee of Hainan Cancer Prevention and Treatment Association 
Standing member of the First Session of the Colorectal Cancer Professional Committee of Hainan Cancer Prevention and Treatment Association 
Standing member of the First Committee of Tumor Immunity and Precision Therapy Professional Committee of Hainan Cancer Prevention and Treatment Association 
Standing member of the MDT Professional Committee of Hainan Cancer Prevention and Treatment Association 
Standing member of the First Committee of Lung Cancer Professional Committee of Hainan Cancer Prevention and Treatment Association 
Standing member of the Lung Cancer Specialized Committee of China Geriatric Healthcare Association 

1.Efficacy Observation of Oxaliplatin Combined with Calcium Folinate and Fluorouracil 5-fluorouracil in the Treatment of Advanced Gastric Cancer, Wei Zhixia. 
2.Reverse Effect of Tetramethylpyrazine on Multi-drug Resistant Strain SM7721_ADM in Liver Cancer, Wei Zhixia.
3.Clinical Study of Continuous Intravenous Infusion of High-dose CF 5-FU in the Treatment of Advanced Gastric Cancer, Wei Zhixia. 
4.Clinical Observation of Megestrol in the Treatment of Advanced Cancer Pain, Tian Ren, Wei Zhixia. 
5.Mechanism of Resistance to Adriamycin in Human Hepatocellular Carcinoma Cells Cultured in Vitro and Electron Microscopic Morphology, Liu Shunying, Wei Zhixia. 
6.Reversal of Ultidrug Resistance in Hepatocellular Carcinoma Cells by Isobodin, Liu Shunying, Wei Zhixia. 
7.Observations on the Efficacy and Toxicity of FOLFIRI Regimen Chemotherapy in Patients with Advanced Colorectal cancer, Zhang Xiangwei, Wei Zhixia. 
8.Alteration of Electron Microscopic Morphology in Induced Drug Resistance Culture of SMMC-7721 Cells, Wei Zhixia. 
9.P-glycoprotein Changes in Induced Drug Resistance Culture of SMMC-7721 Cells, Wei Zhixia.  
10.Reversal and Mechanism of Multidrug-resistant Strain. in Hepatocellular Carcinoma by α-interferon, Wei Zhixia. 
11.Study on Reversal of Drug Resistance in Hepatocellular Carcinoma Cells by α-interferon and Isoptin, Liu Shunying, Wei Zhixia. 
12.Pingping Ai, Xianhua Xu, Shijie Xu, Zhixia Wei, Shun Tan, Junzhe Li, Overexpression of Wnt7a enhances radiosensitivity of non-small-cell lung cancer via the Wnt/JNK pathway.
13.Xianhua Xu, Shijie Xu, Zhixia Wei, Junzhe Li, Wnt7a inhibits transformed cell proliferation while promoting migration and invasion in non-small cell lung cancer.